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Abstract: Cardiotoxicity is a frequent undesirable phenomenon observed during oncological treat-
ment that limits the therapeutic dose of antitumor drugs and thus may decrease the effectiveness
of cancer eradication. Almost all antitumor drugs exhibit toxic properties towards cardiac muscle.
One of the underlying causes of cardiotoxicity is the stimulation of oxidative stress by chemotherapy.
This suggests that an appropriately designed diet or dietary supplements based on edible plants
rich in antioxidants could decrease the toxicity of antitumor drugs and diminish the risk of cardiac
failure. This comprehensive review compares the cardioprotective efficacy of edible plant extracts and
foodborne phytochemicals whose beneficial activity was demonstrated in various models in vivo and
in vitro. The studies selected for this review concentrated on a therapy frequently applied in cancer,
anthracycline antibiotic—doxorubicin—as the oxidative stress- and cardiotoxicity-inducing agent.
Keywords: cardiotoxicity; cardioprotectants; phytochemicals; antioxidants; anthracyclines
1. Introduction
Cancer remains one of the leading health issues worldwide. According to GLOBO-
CAN, in 2020, there were 19.3 million new cancer cases diagnosed and almost 9.9 million
cancer deaths occurred [1]. Compared to 2018, these estimates increased, respectively
by about 7% and 3% (18.1 million new cases and 9.6 million deaths in 2018 according
to Bray et al. [2]). Cancer also represents an immense economic burden that includes
decreased productivity due to lost working hours, costs of prevention, and costs of
treatment [3]. Therefore, cancer prevention as well as more efficient treatments are of
primary importance.
Modern surgery as an approach to treat cancer was established soon after the discov-
ery of anesthesia in the mid-19th century, while cancer radiotherapy and chemotherapy
were first used in the 20th century [4]. By the mid-20th century, a sufficient body of evi-
dence was accumulated to screen the potential anticancer agents, establish proper models
to test their efficacy, and convince the scientific community that chemotherapy might
become an effective cancer treatment. The second half of the 20th century was marked
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by several major breakthroughs, such as the use of drugs with different modes of action,
the concept of adjuvant therapy, and targeted therapy, with imatinib mesylate—tyrosine
kinase inhibitor—being the first FDA-approved targeted anticancer drug [5,6]. With the
accumulation of knowledge and constant development in diagnostic, preventive, and
treatment regimens, the mortality rates of cancer started to decrease from the 2000s [7].
However, despite its unquestionable successes, chemotherapy is still struggling with
two major issues: anticancer drug resistance and toxicity [8,9]. Chemotherapy can induce
several unpleasant, painful, and severe physical and emotional side symptoms that affect
patients’ quality of life [8,9]. Cardiotoxicity, often observed during anticancer chemother-
apy, is one of the significant, sometimes substantially delayed, medical complications
in cancer survivors after the completion of therapy. The adverse symptoms range from
negligible changes in blood pressure and arrhythmias to cardiomyopathy [10]. Significant
cardiotoxicity has been observed during chemotherapy with most anti-tumor drugs: mitox-
antrone (cardiomyopathy), fluorouracil (cardiac infarction), cyclophosphamide and vinca
alkaloids (necrosis of heart cells) [10]. This side effect is particularly dangerous in the case
of anthracyclines therapy, especially with doxorubicin (DOX).
DOX is a very efficient chemotherapeutic agent, the clinical application of which is lim-
ited by cumulative, dose-dependent injury of the heart muscle that frequently jeopardizes
patients’ life despite successful cancer eradication [11,12]. In a relatively high percentage
of patients (reaching over 30% of the population undergoing therapy), congestive cardiac
failure is observed following chemotherapy, especially when DOX is administered together
with another chemotherapeutics [11]. The cardiotoxicity of anthracyclines, at least to a
degree, is associated with their ability to take part in cyclic redox reactions with molecular
oxygen. As a by-product of some of these reactions, superoxide anion-radical is formed,
which initiates a cascade of reactions involving reactive oxygen (ROS) and reactive nitrogen
(RNS) species [13–15]. Cardiac tissue is particularly sensitive to oxidative stress. It has been
demonstrated that treatment with DOX induced damage of DNA, proteins, lipids, and
cellular structures in cardiomyocytes [16,17]. The particularly vulnerable cellular structures
that are targets for ROS and RNS in cardiomyocytes are mitochondria [18], myofibrils [19],
sarcoplasmic mesh [20], and the nucleus [21,22]. The ultimate effect of such disturbances
may be the apoptosis or necrosis of cardiomyocytes [16]. This damage leads to Type I,
or permanent cardiotoxicity, in contrast with reversible Type II cardiotoxicity, which is
associated with targeted cancer therapies [23].
Therefore, biomarkers (Table 1) that correlate to the level of heart damage are moni-
tored during treatment to control the safe dose of administered cytostatics. This approach
makes it possible not only to evaluate the cardiac damage during chemotherapy, but also
may be exploited to assess the cardioprotective impact of different substances, including
compounds of natural origin (Table 2). One strategy that holds great promise for reducing
cardiotoxicity is the use of cardioprotectants or preparations derived from edible plants.
Since phytochemicals are both well tolerated and often exhibit high antioxidant activity,
they can potentially protect cardiac muscle from the negative effects of oxidative stress.
Table 1. Biomarkers used in the determination of cardioprotective potential of compounds and plant extracts.
Biochemical Marker Function
Changes in the Amount/Activity
of Biomarker That Indicate the
Increase of Cardiotoxicity
Aldehyde reductase Catalyzes the formation of secondarymetabolites of chemotherapeutics ↑
AST—aspartate transaminase Catalyzes the reversible transfer of an α-aminogroup between aspartate and glutamate ↑
Caspase-3 Participates in cell apoptosis ↑
CAT—catalase Catalyzes the decomposition of hydrogen peroxide,prevents the formation free radicals ↓
Carbonyl reductase Catalyzes the formation of secondarymetabolites of chemotherapeutics ↑
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Table 1. Cont.
Biochemical Marker Function
Changes in the Amount/Activity
of Biomarker That Indicate the
Increase of Cardiotoxicity
CK, CPK—creatine kinaze
Indicator of cardiomyocytes necrosis, catalyzes
creatine phosphorylation to phosphocreatine which
is an energy source for muscle cells
↑
CML—Nε-(carboxymethyl)lysine Marker of cardiomyocytes inflammationformed during protein damage ↑
Conjugated dienes Products of lipid peroxidation ↑
GSH—glutathione Major cellular antioxidant ↓
GSH-Px—glutathione peroxidase Catalyzes the decomposition of hydrogenperoxide by glutathione ↓
GST—glutathione S-transferases
Catalyze the conjugation of reduced glutathione
to a wide range of substrates, usually
resulting in detoxification
↓
LDH—lactate dehydrogenase Participates in lipid peroxidation ↑
MDA and other substances reacting
with thiobarbituric acid (TBARS) Products of lipid peroxidation ↑
Myeloperoxidase
Catalyzes the oxidation of some carcinogens
using hydrogen peroxide, plays an important
role in their biotransformation
↑
NFκB p50/p65—transcription factor Apoptosis inhibitor ↑
SOD—superoxide dismutase Catalyzes dismutation of superoxide anion radical ↓
TNF-α—tumor necrosis factor Cytotoxic for cancer cells ↑
Troponin I Inhibitory subunit of the troponin complex, actingto inhibit actin-myosin interaction ↑
Arrow upwards—increase in cardiotoxicity biomarker, arrow downwards—decrease in cardiotoxicity biomarker.
Table 2. Structures of some phytochemicals with documented cardioprotective potential.
Compound Structure Ref.
Lycopene
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2. Cardioprotective Potential of Fo ds and Phyt chemicals during DOX Chemotherapy
Nutrition is one of the most important factors for maintaining good health, but it also
plays a pivotal role in the recovery from diseased state. There is a growing awareness that
a better understanding of how to use dietary eans to support patients during therapy
is urgently needed. Oncological patients are a special case, as medical benefits are often
outweighed y he deleterious impact on quality of life [32].
This review evaluates fruits, vegetables, herbs, mushrooms, nd isolated hytochemi-
cals that display protective prop rti s t wards the c rdiac muscle during chemotherapy
with DOX. It is proposed that the intake of non-toxic p rified phytochemicals or prepa-
rations based on foods rich in antioxidants could protect oncological patients against
undesirable side effects of chemotherapy associated with oxidative stress. Only edible
plants and isolated substances for which clinical or pre-clinical studies or in vitro experi-
ments with the use of cardiomyocytes or cell lines derived from the heart tissue of animal
embryos were carried out are included in the review. Since the actual numerical data
derived from studies employing different experimental models are difficult to compare,
we recalculated the published values in the reference to no-treatment-control levels re-
garded as 100%. In this way, it is easy to assess to what extent DOX treatment impairs the
redox homeostasis of cardiomyocytes and how successfully it is restored by treatment with
evaluated cardioprotectants.
2.1. Cardioprotective Potential of Fruits
2.1.1. Grapes
Epidemiological studies suggest that grapes (Vitis vinifera L.) exhibit anti-carcinogenic
properties, mostly due to the presence of resveratrol, the most biologically active compound
found in these fruits [33,34]. Newer data indicate that resveratrol is also able to protect the
hearts of mice against damage induced by DOX during cancer treatment [35,36]. Similarly,
grape seed extract (GSE), containing proanthocyanidines, displayed cardioprotective effects
during therapy with DOX. This was confirmed by the results of experiments in which mice
were treated with DOX (20 mg/kg/day), grape seed extract (100 mg/kg/day orally for
9 days) or DOX in conjunction with grape seed extract (100 mg/kg/day for 7 days before
and 2 days after DOX administration). During the study, creatine kinase (CK) activity
was measured, whose elevated level is a biomarker of cardiac muscle damage (Table 3).
These experiments demonstrated that the administration of GSE to animals prior to DOX
treatment could play a cardioprotective role due to the inhibition of creatinine kinase
activity [37]. In addition, such an experimental regime resulted in the decrease in DNA
fragmentation in heart cells of mice exposed to DOX [37,38].
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Table 3. Creatine kinase (CK) activity in mice treated with DOX in combination with grape seed
extract (GSE) [37].
Group % CK Activity a
Control 100 ± 2.4
GSE No change compared to the control
DOX 589.6 ± 60.7
GSE + DOX + GSE 142.4 ± 19.1
a 100% CK activity = 1009 U/L.
The cardioprotective potential of grape seed proanthocyanins (GSP) was also observed
in the experiments conducted by Ammar et al. [39], in which rats were treated with saline
(1 mL/kg/day) for 9 days, DOX (15 mg/kg, i.p. as a single dose), GSP (70 mg/kg/day,
orally for 9 days) or received GSP (70 mg/kg/day, orally) for 9 days and DOX (15 mg/kg,
i.p.) on the 7th day 1 h after GSP administration. The study showed that GSP normalized
serum biochemical markers of cardiotoxicity such as CK and LDH [39] as well as improved
myocardial tissue antioxidant status (Figure 1). These experiments suggest the mechanism
by which GSP ameliorate DOX-induced cardiotoxicity and it is mainly attributed to its
antioxidative properties where GSP scavenged free radicals and blocked lipid peroxidation.
The protective action of grapes was confirmed by the study on the effectiveness of wine
polyphenolic compounds in mitigating DOX-induced cardiotoxicity by the Nrf2-dependent
down-regulation of TGF-β regulation in rats. Namely, wine polyphenolic compounds im-
proved the failing cardiac function and cardiac hypertrophy induced by DOX, reduced the
extracellular matrix accumulation, and inhibited DOX-induced cardiac fibrosis, attenuated
DOX-triggered oxidative stress and increased the levels of antioxidant enzyme activities,
as well as inhibited DOX-induced mitochondria-dependent apoptosis [40].
Figure 1. The oxidative-stress-associated cardiotoxic effects of DOX (left-hand side bars) are com-
pared with cardioprotective activity of fruit extracts (right-hand side bars). Fruit extracts decreased
MDA formation stimulated by DOX (control MDA values ranged from 7.92 to 182.65 nmol/g protein).
The tested cardioprotectants restored the reduced by DOX level of GSH (control GSH values range
was from 27.51 to 35.87 mg/g protein) as well as normalized activity of antioxidant enzymes SOD
and CAT (100% CAT and SOD were in the range from 30.95 to 50.29 U/g protein and from 13.78 to
155.5 kU/mg protein, respectively).
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2.1.2. Pomegranate
Pomegranate (Punica granatum L.) is a nutrient-dense fruit rich in phytochemicals such
as punicalagin, ellagitannins, anthocyanins, tannins, hydrolysable tannins, and punicic
acid [41]. These phenolic compounds have attracted increasing attention as preventive
agents for various oxidative-stress-related diseases. Therefore, pomegranate polyphenols
could be a good candidate in preventing cardiotoxicity initiated by DOX. The cardioprotec-
tive effect of whole fruit extract of pomegranate (WFEP) was investigated in rat model [42].
Investigations included three groups of rats: the control (received water), DOX (received
10 mg/kg DOX through the femoral vein on day 16) and WFEP + DOX group (received
100 mg/kg/day WFEP orally for 18 days and on 16th day 10 mg/kg DOX).
This study revealed that the administration of whole fruit extract of pomegranate
along with DOX restored QT interval, heart enzyme activity, markers of redox imbalance
(Figure 1) and histopathological properties in rats to the control level and concluded that
WFEP could exhibit cardioprotective properties.
2.1.3. Hawthorn
Hawthorn (Crataegus species) has been used in folk medicine for centuries as a rem-
edy, which treats cardiovascular diseases, cancer, diabetes, hyperlipidemia, and sexual
weakness [43–45]. Flavonoids and procyanidins are the main active hawthorn compounds.
The antioxidant properties of the aqueous extract of Crataegus aronia (CAE) in the con-
text of protection against cardiotoxic effects of DOX were determined in albino Wistar
rats [46]. Investigations included six groups of rats: control (received normal saline, for
28 days), CAE (were administered 200 mg/kg/d of CAE for 14 consecutive days, by oral
gavage, then normal saline i.p. for the next 14 days), DOX (received accumulative dose
of 15 mg/kg DOX in 6 equal i.p. injections (2.5 mg/kg every 2 days) over 14 consecutive
days), DOX + CAE (received combined treatment of CAE and DOX for 14 consecutive days
with the same doses and routes of administration as previously mentioned), CAE postDOX
(were administered an accumulative dose of DOX (15 mg/kg) i.p. for the first 14 days,
then a daily dose of CAE (200 mg/kg) orally for the next 14 days) and CAE preDOX
(were administered a daily dose of C. aronia (200 mg/kg) for 14 days, then treated with an
accumulative dose of DOX (15 mg/kg) i.p. for the next 14 days). The prevention and/or
treatment of DOX-induced cardiotoxicity and heart failure were followed, and based on
the obtained results, it was concluded that the administration of the aqueous extract of
C. aronia with or following DOX augmented the endogenous antioxidant components of
the rat heart and ameliorated DOX-induced cardiotoxicity (Figure 1).
2.1.4. Grapefruit
Findings from epidemiological studies suggest an association between grapefruit
(Citrus paradisi L.) consumption and reduced risk of coronary heart disease mortality [47].
In addition to the wide range of essential vitamins and minerals, grapefruit is rich in
carotenoids and flavonoids. Since all these compounds are powerful antioxidants, ethanolic
seed extract of grapefruit was assessed as an effective attenuator of DOX-induced oxidative
stress in rat heart [48]. Adult male Sprague Dawley rats were divided into four groups:
control (CON) was given peanut oil (vehicle), 0.5 mL daily by gastric gavage for 14 days;
the second group received ethanol extract of grapefruit seed extract (GSE), 20 mg/kg/day
by gastric gavage for 14 days; the third received DOX 20 mg/kg (i.p. single dose) following
gastric gavage of GSE, 20 mg/kg/day for 14 days; the fourth and last group also had single
dose i.p. DOX 20 mg/kg, but following the administration of peanut oil, 0.5 mL daily by
gastric gavage for 14 days. The rats were sacrificed, and enzymatic and non-enzymatic
cardiac antioxidants were determined (Figure 1). The results showed that pretreatment
with GSE for 14 consecutive days caused the amelioration of all biochemical parameters
altered by DOX, and such findings suggest a possible use of GSE in the prevention of
DOX-induced cardiomiopathy.
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2.2. Cardioprotective Potential of Vegetables
2.2.1. Garlic
Garlic (Allium sativum L.) is a very popular vegetable that has been consumed since an-
tiquity. Its regular intake reduces cholesterol, thereby decreasing the risk of cardiovascular
diseases. Garlic is also known to exhibit antitumor, antimicrobial [49], and antioxidant [50]
properties. Garlic co-administration was also shown to decrease DOX toxicity towards
cardiac muscle cells [51]. The cardioprotective activity of garlic in rats treated with DOX
was compared with that of probucol (PRO), which is a powerful antioxidant itself, but
also increases the level of endogenous antioxidants [25]. In addition, by increasing the rate
of LDL catabolism, this drug lowers the levels of cholesterol and triacyclglycerols in the
bloodstream. Therefore, PRO is often used to protect heart cells during chemotherapy with
anthracyclines [52]. In these studies, DOX (30 mg/kg i.p.) was administered in conjunction
with PRO (cumulative dose 120 mg/kg administered in 12 doses for 30 days i.p.) or with
garlic homogenate orally administered for 30 days at amounts of 250 mg/kg/day (G-250) or
500 mg/kg/day (G-500). The protective activity was assessed based on the measurements
of oxidative stress biomarkers in rat hearts (Table 4).
Table 4. Levels of cardiotoxicity biomarkers in rats treated with DOX in combination with probucol (PRO) or garlic
homogenate (G-250, G-500) [52].











CON 100.0 ± 5.7 100.0 ± 8.5 100.0 ± 5.9 100.0 ± 11.5 100.0 ± 20.7 0.0
DOX 161.9±17.1 143.6 ± 2.5 27.9 ± 7.5 66.0 ± 7.7 43.0 ± 1.0 4.0
PRO + DOX 71.5 ± 6.5 105.9 ± 3.6 29.8 ± 4.0 90.3 ± 11.5 81.9 ± 15.5 1.6
G-250 + DOX 50.9 ± 8.5 93.4 ± 3.9 50.8 ± 6.7 88.4 ± 25.0 77.2 ± 15.5 2.8
G-500 + DOX 136.2 ± 9.7 131.4 ± 2.4 31.1 ± 6.5 110.6 ± 13.5 91.7 ± 5.2 2.9
a 100% MDA = 203.03 nmol/g m.w.; b 100% GSH = 479.17 µg/g m.w.; c 100% CAT activity = 49.49 U/mg protein; d 100% SOD
activity = 6.88 U/mg protein; e 100% activity GSH-Px = 0.193 U/mg protein.
The results demonstrated that the level of monitored markers in animals treated with
DOX and garlic closely resembled the results obtained for the rat group treated with DOX
and PRO. Hence, garlic can play a cardioprotective role, as it prevents DOX toxicity towards
heart cells equally as effectively as the currently clinically used cardioprotectant.
2.2.2. Tomato
Tomatoes (Lycopersicon esculentum L.) are popular diet components in many coun-
tries. This vegetable is a rich source of carotenoid—lycopene (Table 2)—as well as
flavonol—quercetin—and vitamins A and C. Due to the fact that it reduces the properties
of these phytochemicals, it was presumed that tomato extract and purified lycopene may
ensure protection against cardiotoxicity stimulated by DOX. To verify this hypothesis,
experiments were performed in which mice were treated with either DOX (15 mg/kg
i.p.) or DOX together with tomato extract (1.2 g/kg or 2.4 g/kg administered i.p. 1 day
before and 3 days after DOX treatment) or DOX with lycopene (1.7 mg/kg or 3.5 mg/kg
administered i.p. 1 day before and 3 days after DOX treatment). CK activity was measured
(Table 5) and the histopathological examination was executed [24].
Table 5. Effect of tomato extract (TE) and lycopene (LYC) on DOX-induced CK level changes in
mice [24].
Group % CK Activity a
CON 100.0 ± 6.6
DOX 781.4 ± 99.2
TE (1.2 g/kg) + DOX + TE 425.5 ± 30.5
TE (2.4 g/kg) + DOX + TE 256.1 ± 24.0
LYC (1.7 mg/kg) + DOX + LYC 464.2 ± 33.2
LYC (3.5 mg/kg) + DOX + LYC 243.6 ± 25.9
a 100% CK activity = 192.3 U/L.
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The increased levels of CK were observed in animals treated with DOX. However,
the results confirmed that tomato extract and lycopene co-administered with DOX to a
significant degree decreased the activity of CK in a dose-dependent manner. In addition,
the results of histopathological examination revealed that animal tissue treated with DOX
together with tomato extract or lycopene at higher doses were characterized by the lower
susceptibility of heart cells to necrosis compared to heart tissue sections from mice who
were administered DOX only [24]. Alternative approaches have demonstrated the ability
of lycopene to protect heart tissue affected by DOX [53]. During these experiments, rats
were treated with DOX (10 mg/kg i.p.) or DOX with lycopene in two schemes. In the first,
lycopene (4 mg/kg) was administered via indenter in corn oil for 10 days before treatment.
In the second, lycopene was applied in the same way, but for 2 days before and 3 days
after DOX treatment. The biochemical evaluation of heart sections demonstrated that the
administration of lycopene during DOX therapy was particularly beneficial (Figure 2).
Histopathological examination indicated, among other effects, a reduction in interstitial
edema and degenerative states in the rats treated with lycopene and DOX as compared
with hearts from rats treated with DOX only.
Figure 2. The oxidative-stress-associated cardiotoxic effects of DOX (left-hand side bars) are com-
pared with cardioprotective activity of bioactive phytochemicals (right-hand side bars). Phyto-
chemicals decreased MDA formation stimulated by DOX (control MDA values ranged from 57.7
to 1179 nmol/g protein). The tested cardioprotectants restored the level of GSH reduced by DOX
(control GSH values range was from 0.01 to 99.8 µmol/g protein), as well as normalized activity of
antioxidant enzymes SOD and CAT (100% CAT and SOD were in the range of 5.82 to 12.35 U/mg
protein and from 1.10 to 8.69 U/mg protein, respectively).
These results suggest that lycopene and tomato extract may protect the heart muscle
against DOX toxicity [53]. According to Karimi et al. [24], such beneficial properties result
from the neutralization of free radicals and inhibition of lipid peroxidation. In these studies,
the administration of the popular food component was particularly valuable, indicating
the potential of a proper diet to aid in the efficient protection of oncological patients from
the toxic side effects of chemotherapy.
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2.2.3. Spinach
The wide variety of flavonoids in spinach (Spinacia oleracea L.) are responsible for the
antioxidant properties of this vegetable [54]. The spinach phytocomplex was thus also
proposed to be capable of preventing DOX toxicity of the heart muscle [55]. The mice were
administered DOX (20 mg/kg i.p.) or DOX in conjunction with the spinach extract (ES) in a
dose of 10 mg/kg/day. ES was given i.p. for 7 days before and 6 days after DOX treatment
or only 6 days after DOX treatment. Table 6 summarizes the results of measurements
regarding biochemical oxidative stress biomarkers.
Table 6. Effect of administering spinach extract (ES) on changes in the level of biomarkers of
cardiotoxicity induced by DOX in mice model [55].







CON 100.0 ± 10.3 100.0 ± 9.6 100.0 ± 13.4 100.0 ± 21.2
ES 96.0 ± 5.6 106.4 ± 11.7 118.0 ± 18.0 100.5 ± 5.4
DOX 148.0 ± 12.9 152.0 ± 15.9 143.6 ± 15.6 91.1 ± 12.6
ES + DOX + ES 111.5 ± 7.4 105.3 ± 8.5 196.4 ± 14.5 133.0 ± 14.1
DOX + ES 123.4 ± 11.5 128.7 ± 15.9 138.3 ± 18.0 100.2 ± 13.4
a 100% MDA = 8.2 nmol/mg protein; b 100% CAT activity = 0.94 OD240 nmol/mg protein; c 100% Cu/Zn SOD
activity = 20 U/mg protein; d 100% GSH-Px activity = 413 mU/mg protein.
The study confirmed the potential of spinach to protect heart cells from the toxic effects
of DOX therapy. The histopathological observations and biochemical markers indicated
that the most effective heart protection by spinach components occurred in animals that
were administered ES before and after DOX treatment. In these animals, the lowest level of
lipid peroxidation and the strongest stimulation of activity of antioxidant enzymes were
observed [55].
2.2.4. Beetroot
Beetroot (Beta vulgaris L.) is a rich source of betalains—water-soluble pigments con-
taining heterocyclic nitrogen atoms in their structure. Purple red betacyanins and yellow
betaxanthins belong to the group of betalains [56]. Betanin is a phytochemical occurring in
beetroot in the highest concentration among all betalains. Other substances present in high
concentrations in the peel of this vegetable are phenolic acids, e.g., p-coumaric acid and
ferulic acid [57]. All these components display high antioxidant activity and were shown
in vivo in mouse model to inhibit the development of skin and lung cancer. It is suggested
that these beneficial properties resulted from the presence of betalains [58].
The cardioprotective properties of beetroot were tested in leukemia-bearing mice
treated with DOX [59]. Two experimental schemes were tested (Figure 3). In the first,
healthy mice were given beetroot juice to drink ad libitum instead of water for 7 days,
then were administered a toxic dose of DOX (20 mg/kg i.p.) for 2 or 20 h. After this time,
the level of DNA damage in cardiomyocytes was determined. The results of comet assay
revealed very strong DNA fragmentation in the cardiomyocytes of the mice treated with
DOX. This genotoxic effect was significantly decreased in the animal groups treated with
anthracycline in conjunction with beetroot juice.
In the second scheme, mice bearing leukemia L1210 were tested. In these experiments,
the animals were treated with either DOX (therapeutic dose of 7.5 mg/ kg i.p.), or beetroot
juice, or DOX in conjunction with beetroot juice. Survival for 120 days was considered to
indicate a complete cure. The results of these experiments indicated that treatment with
DOX alone significantly prolonged the lifespan of leukemia-bearing mice; however, none of
the animals reached the 120-day lifespan threshold. In contrast, in animal groups in which
DOX administration was combined with beetroot juice, complete cures were observed in
about 50% of the mice. These results suggest that simple dietary intervention might be a
very effective means to protect oncological patients against undesirable effects of oxidative
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stress. After the completion of clinical studies, this intervention could be recommended to
cancer patients undergoing chemotherapy.
Figure 3. Experimental schemes for assessment of cardioprotective properties of beetroot tested in
leukemia-bearing mice treated with DOX.
2.3. Cardioprotective Potential of Medicinal Mushrooms
The cardioprotective role of medicinal mushrooms in DOX-induced cardiotoxicity
has been evaluated for Ganoderma lucidum Karst (Reishi), a popular edible mushroom
widely used for the general promotion of health and longevity in Asian countries. Several
studies documented the anti-cancer potential of extracts and fractions of G. lucidum [60–62]
and suggested their potential as an alternative therapy for breast and prostate cancer.
Ganoderma lucidum extract (GLE) was also shown to be active in preventing DOX-associated
cardiotoxicity, as determined by the monitoring of several cardiac toxicity biomarkers [63].
In addition, histological observations, hematology profiles, and electrocardiography pa-
rameters supported the protective effect of GLE against cardiotoxicity associated with
DOX treatment [63]. Another study reported that davallialactone (DAVA) extracted from
the mushroom Inonotus xeranticus (Bull.) Karst significantly increased the viability of
DOX-injured H9c2 cells, and inhibited DOX-induced ROS production, apoptosis, and the
expression of Cu/Zn SOD and Mn-SOD. DAVA also inhibited the expression of extra-
cellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), which were
activated by DOX. In an animal model, treatment involving DAVA significantly reduced
cardiomyocyte lesions [64].
2.4. Cardioprotective Potential of Wheat
Wheat (Triticum species) is one of the most important cereal crops in the world. Eaten
as a whole grain, it has been claimed to reduce the risk of cardiovascular disease, type 2 dia-
betes, and cancer due to its content containing unique health-promoting components, such
as phenolic acids and flavonoids [65]. Considering their prophylactic actions against oxida-
tive stress, the cardio-protective role of chemically standardized total polyphenolic extract
of whole wheat grains (WWGPE) in DOX-induced cardiotoxicity was tested employing
appropriate in vitro and in vivo preclinical assays [66]. Beneficial effects of wheat polyphe-
nols on ROS accumulation, lipid peroxidation, protein carbonylation, endogenous redox
systems as well as on intrinsic and extrinsic apoptotic signaling were proven in isolated
rat cardiomyocytes exposed to DOX (1 µM). In vivo study was conducted on Wistar rats
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treated with distilled water containing 2% Tween 80, (p.o.) as the control. Purified forms of
the most abundant phenolic components of the extract, i.e., ferulic acid (100 mg/kg, p.o.) or
apigenin (100 mg/kg, p.o.) as reference or polyphenolic extract WWGPE (100 mg/kg, p.o.)
were administered once daily for 7 consecutive days prior to DOX. DOX (3 mg/kg, i.p.)
was administered on every alternative day for a total of three doses. According to such a
study design, all findings obtained under in vitro conditions were confirmed in vivo, with
an emphasis on the superior cardioprotective effect of WWGPE compared to ferulic acid
and apigenin (Table 7).
Table 7. Effects of wheat polyphenols (polyphenolic extract of whole wheat grains—WWGPE; ferulic
acid—FA; apigenin—API) on changes in biochemical parameters such as cardiotoxicity biomarkers
induced by DOX in rat model [65].









CON 100.0 ± 9.9 100.0 ± 11.0 100.0 ± 11.2 100.0 ± 10.6 100.0 ± 10.6
FA 98.7 ± 10.6 98.8 ± 9.7 100.1 ± 10.3 100.0 ± 22.0 97.9 ± 12.8
API 98.3 ± 8.8 106.1 ± 11.2 97.9 ± 10.4 100.8 ± 12.9 100.0 ± 6.4
WWGPE 98.4 ± 9.9 103.5 ± 10.8 97.0 ± 10.7 102.3 ± 162.1 93.6 ± 6.4
DOX 129.9 ± 12.2 137.8 ± 13.6 135.9 ± 15.1 162.1 ± 17.4 142.5 ± 17.0
DOX + FA 112.4. ± 11.6 116.2 ± 11.9 115.8 ± 10.6 137.8 ± 14.4 121.3 ± 10.6
DOX + API 114.9 ± 11.9 119.0 ± 12.4 118.2 ± 11.0 135.6 ± 8.3 121.3 ± 14.9
DOX + WWGPE 108.3 ± 11.5 112.8 ± 10.2 112.6 ± 9.6 130.3 ± 11.4 110.6 ± 10.6
a 100% LDH = 173.33 U/l; b 100% CK = 32.04 IU/mg protein; c 100% AST = 47.17 IU/l; d 100% Troponin
I = 1.32 ng/mL; e 100% Troponin T = 0.47 pg/mL.
2.5. Cardioprotective Potential of Herbs and Spices
2.5.1. Ginkgo Biloba
Japanese ginkgo (Ginkgo biloba L.) is a unique tree that has been used in Chinese
medicine for over 5000 years. Components found in its leaves, mainly flavonoids and
terpenoids (e.g., ginkgolid B) are characterized by high antioxidant activity. In addition,
ginkgo exhibits anti-angiogenic properties and influences gene expression in a way that
may support cancer chemoprevention [67]. The administration of ginkgo extract during
DOX therapy prevented the development of cardiomyopathy in rats [68]. Jasim [69]
reported that ginkgo extract given to mice submitted to DOX treatment had the following
beneficial effects on heart functioning: a decrease in lipid peroxidation in heart cells,
the restored activity of enzymes involved in ROS neutralization to the normal level, the
reversal of undesirable changes observed in ECG, and the occurrence of only minimal
structural changes in the heart. These results supported the use of ginkgo extracts rich
in flavonoids as a dietary supplement for limiting cardiotoxicity induced by DOX in
oncological patients [68]. To corroborate the cardioprotective action of G. biloba (GB) against
acute DOX-induced cardiotoxicity, another study was conducted on rats [69]. Within this
study, rats were treated with distilled water, 5 mL/kg/day, orally for 10 days or with
distilled water, 5 mL/kg, orally for 10 days and on the 8th day they received a single
intra-peritoneal injection of DOX (20 mg/kg). The solution of GB (100 mg/kg/day) was
applied over 10 days before and after DOX treatment. Changes in cardiac biomarkers due
to the co-administration of GB with DOX are shown in Table 8.
Table 8. Changes of cardiac biomarkers due to co-administration of Ginkgo biloba (GB) with doxoru-
bicin in rats [69].









CON 100.0 ± 37.6 100.0 ± 15.9 100.0 ± 20.1 100.0 ± 47.9 100.0 ± 18.1
DOX 172.7 ± 67.3 58.5 ± 17.4 247.1 ± 44.3 161.1 ± 38.7 185.1 ± 34.4
GB + DOX + GB 145.4 ± 13.6 77.3 ± 13.4 192.9 ± 24.8 146.7 ± 16.5 153.0 ± 31.6
a 100% MDA = 1.1 nmol/L; b 100% GSH = 24.83 pmol/L; c 100% Troponin I = 17 ng/L; d 100% TNF-α = 23.17 ng/L;
e 100% caspase-3 = 13.33 pmol/L.
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2.5.2. Red Sage
Red sage (Salvia miltiorrhiza Bunge) is a medicinal plant widely applied as a remedy
in cardiovascular diseases in traditional Chinese medicine [70]. In herbology, its roots
are mainly used. The major bioactive components of red sage are salvianic acids (SAs),
including salvianic acid A, salvianic acid B, rosmarinic acid, and other phenolic acids.
SAs belong to strong antioxidants that decrease the level of lipid peroxidation and dis-
play the ability to scavenge hydroxyl radicals [71]. A preparation of salvianic acids was
tested to determine their cardioprotective properties in mice exposed to DOX. Animals
were administered DOX only (15 mg/kg) or DOX in conjunction with SAs (40 mg/kg);
the latter were administered to animals immediately after drug treatment and then for
two consecutive days. The protective activity of SA preparation was assessed based on
histological observations of heart tissue, changes in ECG, the measurements of antioxidant
activity of phenolic acids, and CK activity. In groups of animals treated with DOX only, the
formation of cytoplasmatic vacuoles, myofibrillar loss, and undesirable changes in ECG
typical for DOX-induced cardiomyopathy occurred. The single DOX dose also increased
the level of free radicals in heart muscles, MDA level, and CK activity. In contrast, the
administration of DOX together with SAs resulted in a decrease in heart muscle damage,
the normalization of ECG, and a decrease in MDA level and CK activity. These results
suggest that SA preparation can ensure the protection of the heart during DOX therapy [72].
2.5.3. Saffron
Saffron (Crocus sativus L.) has been frequently used as a spice and medicinal plant
to promote human health for a long time. Its antioxidant activity originates from two
bioactive compounds, crocin and safranal [73]. Saffron extract was shown to possess anti-
inflammatory, anti-atherosclerotic, antigenotoxic, and cytotoxic activities [74,75]. Likewise,
findings obtained from a study on DOX-treated rabbit hearts demonstrated that saffron
extract improved the cardiomyocyte survival and function, preserved cardiac troponin
T proteins, inhibited the p38 MAPK pathway, and activated the AKT/mTOR/4EBP1
pathway [76].
2.5.4. Ginger
Ginger (Zingiber officinale Roscoe) is a spice widely used all over the world. It contains
various chemical constituents, including phenols, terpenes, polysaccharides, lipids, organic
acids, and raw fibers. The health benefits (antioxidant, anti-inflammatory, antimicrobial,
and anticancer activity) of ginger are mainly attributed to its phenolic compounds, such
as gingerols and shogaols [77]. As a very potent remedy, it could be of great interest in
different cardioprotective aspects. Ajith et al. [78] followed the activity of ginger aqueous
ethanol extract in the context of acute cardiac damage in rats caused by DOX. Protection
was estimated by measuring the level of cardiac MDA, as well as AST and LDH activities.
The obtained results concluded that ginger ameliorated DOX-induced cardiotoxicity [78].
2.5.5. Phyllanthus urinaria
Plants of the genus Phylanthus (Euphorbiceae) originate from tropical and subtropical
regions. They have long been used in Thai folk medicine to treat kidney and urinary blad-
der disturbances, intestinal infections, diabetes, and hepatitis B. One of the representatives
is Phyllanthus urinaria L. (PU), a plant that is rich in alkaloids, flavonoids, lignans, phenols,
and terpenes [79]. In extracts from this plant, the following compounds were identified:
N-octadecan, β-sitosterole, ellagic acid, kaempferol, quercetin, gallic acid, rutin [80], corila-
gin, isostrictinin, geraniin [81] and others. Components of Phyllanthus were reported to
protect the heart against DOX toxicity [25,82]. Specifically, the antioxidant activity of PU in
the context of protection against cardiotoxic effects of DOX was determined in the heart
myoblast cell line H9c2 [25]. The H9c2 cell line is derived from heart tissue of rat embryos.
It retains several features characteristic of heart muscles and therefore is considered a good
model of this tissue. During these studies, the cells were pre-incubated with ethanolic
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extract of PU (1 µg/mL or 10 µg/mL for 30 min). The cells were then treated with DOX
(10−9–10−5 mol) and incubated for 48 h. The results of these experiments are shown in
Table 9. The protective properties of PU extract were compared with those of vitamin C
and N-acetylcysteine, whose antioxidant activity has been well documented (Figure 2).
Table 9. The level of cardiotoxicity biomarkers in H9c2 cells treated with 1 µM DOX in combination
with ethanolic Phyllanthus urinaria L. (PU) extract in various combinations [25].







CON 100.0 ± 2.9 100.0 ± 2.3 100.0 ± 0.2 100.0 ± 4.0
PU 1
(1 µg/mL) 89.4 ± 1.8 213.5 ± 1.9 151.6 ± 2.2 136.8 ± 9.6
PU 10
(10 µg/mL) 88.5 ± 2.7 269.2 ± 3.8 170.7 ± 0.0 169.4 ± 12.4
DOX 289.0 ± 2.6 5.6 ± 3.4 32.6 ± 0.4 40.8 ± 1.5
PU 1 + DOX 55.6 ± 2.5 164.7 ± 0.8 147.3 ± 2.8 128.6 ± 8.5
PU 10 + DOX 30.7 ± 2.1 244.4 ± 7.1 160.9 ± 0.6 161.6 ± 11.7
a 100% MDA = 1.179 nmol/mg protein; b 100% GSH = 0.266 nmol/mg protein; c 100% SOD activity = 5.817 U/mg
protein; d 100% CAT activity = 11.854 nmol/min/mL/mg protein.
The antioxidant activity of PU was higher than that of vitamin C or N-acetylcysteine,
which suggests that extracts from this herb could be used to prevent cardiotoxicity induced
by DOX. Additionally, during these studies, the cytotoxicity of combined therapy and the
level of transcription factor NF-κB p50/p65 (marker of inflammation) were determined. It
was observed that PU significantly decreased the cytotoxic effects of DOX in H9c2 cells,
especially in combination with a higher concentration of this herb extract. The stimulation
of NF-κB expression by DOX was fully inhibited by PU, which indicated yet a different
mechanism of protection of H9c2 cells [25].
2.5.6. Spirulina
Spirulina (Spirulina platensis (Gomont) Geitler) is a primitive blue–green seaweed
characterized by a high content of nutrients and phytochemicals [83]. Due to its high
content of protein, calcium, iron, and β-carotene, it is often used in the production of
dietary supplements. Its biological activity, and above all its strong antioxidant and anti-
inflammatory activity, can be attributed to compounds such as fatty acids (n−3, n−6),
β-carotene, α-tocopherol, phycocyanin, and phenolic compounds [15]. Recent studies
suggest that spirulina counteracts DOX-induced cardiotoxicity and, therefore, may improve
the therapeutic index of this drug [84]. Khan [16] conducted experiments treating mice i.p.
with either DOX (4 mg/kg/week for 4 weeks) or spirulina (250 mg/kg, orally, twice a day
for 7 weeks), or DOX in conjunction with spirulina (250 mg/kg, orally, 3 days before DOX
treatment and 7 days with DOX). The results of this study are shown in Table 10.
Table 10. The effect of DOX and spirulina on the level of cardiotoxicity markers in Wistar rats [16].
Group MDA Level [%] a % SOD Activity b % GSH-Px Activity c
CON 100.0 ± 13.9 100.0 ± 4.2 100.0 ± 7.1
DOX 167.4 ± 21.9 76.7 ± 8.2 72.6 ± 4.9
spirulina 101.6 ± 12.3 95.8 ± 3.7 102.7 ± 10.4
spirulina + DOX 138 ± 9.1 100.5 ± 6.3 92.8 ± 11.1
a 100% MDA = 18.7 nmol/g heart tissue; b 100% SOD activity = 37.8 U/mg protein; c 100% GSH-Px
activity = 56.6 nmol/mg protein.
The combined DOX and spirulina treatment resulted in a significant reduction in
the level of mouse heart muscle damage, such as the loss of myofibrils, the formation
of vacuoles in the cytoplasm, and the enlargement of the mitochondria. In addition, it
contributed to protection against lipid peroxidation, influenced restoring the proper activity
of enzymes responsible for antioxidant protection, and reduced mortality in this group
of mice.
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Khan [16] also tested spirulina for its potential cardioprotective effect towards DOX-
treated Wistar rats. In their study, rats were treated with either DOX (2 mg/kg, in-
travenously for 5 days, followed by weekly once for 2 weeks) or DOX with spirulina
(1000 mg/kg feed by enteral route for 7 days followed by the intravenous injection of
DOX; spirulina supplementation was continued for 19 days) or DOX in conjunction with
spirulina (250 mg/kg, orally, 3 days before DOX treatment and 7 days with DOX). The
results of this research (Table 10) indicate the potential of spirulina supplements to reduce
cardiotoxicity during DOX cancer chemotherapy.
2.6. Cardioprotective Dietary Supplement—CardiPro
CardiPro is an herbal preparation manufactured by Square Pharmaceuticals Ltd.
(Bangladesh). It contains extracts from five herbs, 12.5% Boerhaavia diffusa L., 12.5%
Ocimum sanctum L., 25% Emblica officinalis Gaertn., 25% Withania somnifera (L.) Dunal, and
25% Terminalia arjuna (Roxb.) Wight & Arn. Each of these herbs, tested separately, dis-
played certain biological properties with potential for protecting human organisms against
cardiovascular diseases. Mohan [85] tested the effects of CardiPro on cardiotoxicity induced
by DOX in mice. The mice were treated with DOX (four doses of 4 mg/kg i.p.), CardiPro
(150 mg/kg, orally 2 times a day for 7 weeks), or DOX in combination with CardiPro (twice
a day for 7 weeks simultaneously with the administration of DOX).
The cardiac muscle was examined for morphological changes, the presence of lipid
peroxidation products, and the level of enzymes responsible for the disposal of free radicals
(Table 11). All biomarkers suggested that despite the use of a non-toxic dose of DOX,
some damage to the cardiac muscle was observed (the loss of myofibrils, the formation of
vacuoles in the cytoplasm, a higher level of MDA, and a decrease in the activity of antioxi-
dant enzymes). The histological lesions in the hearts of mice receiving DOX + CardiPro
treatment were minimal compared to the hearts of the mice in the control group.
Table 11. Effect of CardiPro on lipid peroxidation and the level of antioxidant enzymes in the heart
tissue of DOX-treated mice (cumulative dose 16 mg/kg) [85].
Group MDA Level [%] a % SOD Activity b % GSH-Px Activity c
CON 100.0 ± 11.0 100.0 ± 9.3 100.0 ± 8.0
DOX 130.5 ± 3.7 79.5 ± 4.3 72.0 ± 6.4
CardiPro 79.3 ± 6.1 104.0 ± 2.7 106.0 ± 6.2
DOX + CardiPro 97.0 ± 11.0 101.3 ± 3.2 98.0 ± 3.6
a 100% MDA = 16.4 nmol/g heart tissue; b 100% SOD activity = 37.5 U/mg protein; c 100% GSH-Px
activity = 50 nmol/mg protein.
CardiPro also contributed to the protection of mouse myocardium cells against lipid
peroxidation, and antioxidative enzyme activity returned to normal. The researchers
claimed that the study results demonstrate that CardiPro, a flavonoid-rich herbal prepara-
tion, can be used in the protection of myocardial cells against chronic toxicity induced by
DOX [85].
2.7. Phytochemicals Isolated from Edible Plants with Cardioprotective Potential
2.7.1. Sesamol
Sesamol is a natural phenolic compound found in sesame seeds (Sesamum indicum
L.) and sesame oil. There is increasing body of evidence that shows sesamol may act as
a metabolic regulator that possesses antioxidant, anti-mutagenic, anti-hepatotoxic, anti-
inflammatory, anti-aging, and chemopreventive properties [86]. The modulator role that
sesamol plays against oxidative stress through its radical scavenging ability and lipid
peroxidation lowering potential was tested in rats in which cardiomyopathy was caused by
DOX [87]. In this study, albino Wistar rats were randomly divided into four groups accord-
ing to design: control—received normal saline (10 mL/kg body weight p.o.); SES—received
sesamol 50 mg/kg body weight i.p. for 7 days and then alternatively with a vehicle for the
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next 2 weeks; DOX—treated with DOX (total cumulative dose of 15 mg/kg i.p. for 2 weeks;
SES + DOX—pretreated with sesamol 50 mg/kg body weight i.p. for 7 days followed by
DOX administration as in the DOX group. Sesamol protective action on myocardium was
monitored by several biomarkers; some of them, such as changes of cardiac biomarkers
and antioxidant status, are shown in Figure 2.
2.7.2. p-Coumaric Acid
p-Coumaric acid (PC) is a phenolic phytochemical present in many edible plants
(Table 2). The main sources of this compound are coffee, wine, chocolate, and beer. Due
to its antioxidant activity, research was conducted on the ability of PC to protect the heart
from oxidative stress caused by DOX. Rats received i.p. a single dose of DOX (15 mg/kg),
or PC (100 mg/kg) orally for 5 days, or PC for 5 days followed by DOX. After 24 h from
the end of feeding, the levels of selected cardiotoxicity biomarkers in the heart tissue were
determined (Figure 2).
The administration of DOX alone contributed to a significant increase in the level of
LDH, CPK, and MDA, whereas the administration of PC to animals for 5 days preceding
the administration of anthracycline prevented this effect. The enzymatic activity of SOD
and CAT, as well as the level of GSH in the group of animals treated with DOX alone,
decreased significantly. In the case of rats that received PC before the administration of
DOX, a smaller decrease in these activities was observed. In the group of rats treated with
PC only, no significant changes were observed in the biomarker levels relative to the control
group. Thus, PC is another candidate phytochemical that can play an important role in
counteracting damage to the heart caused by oxidative stress induced by DOX therapy [88].
2.7.3. Curcumin
Turmeric (Curcuma longa L.), a commonly used traditional mixture of Indian spices
and food colorant, is a plant that exhibits cardioprotective properties [89]. This may be
due to its ability to protect cells from oxidative stress, including the avoidance of lipid
peroxidation. The main component of turmeric is diferuloyl methane, commonly named
curcumin (Table 2). Curcumin and its analogues are characterized by a large variety of
physiological and pharmacological effects [90]. These compounds are antioxidants with
anti-inflammatory and anti-infective properties [89].
Venkatesan [90] tested the cardioprotective properties of curcumin in rats exposed to
DOX. The group of animals was administered i.p. a single toxic dose of DOX (30 mg/kg),
curcumin (i.p.), or DOX with curcumin (200 mg/kg 7 days before and 2 days after admin-
istration of DOX). After the experiments were completed, the level of conjugated dienes
and MDA (main lipid peroxidation products), GSH content, and activity of GSH-Px and
CAT in heart cells were determined. The results of the conducted biochemical tests are
shown in Figure 2. These data indicate that the combination of DOX therapy with curcumin
caused the cardiotoxicity markers to remain at control level [91]. Although curcumin was
administered i.p., these studies suggest that turmeric, particularly the curcumin present in
it, could be used as a cardioprotective agent during chemotherapy administered orally in a
form ensuring high bioavailability.
Curcumin effects against DOX-induced cardiotoxicity were also extensively investi-
gated using a myocardial injury model in mice (in vivo) and rat cardiomyocytes (in vitro) [92].
The effects of administering curcumin an hour before DOX administration were evalu-
ated by determining the heart rate and ECG’s ST segments, as well as LDH and CK
activities in serum, caspase-3 activity, apoptosis rate, and histopathological changes of
the myocardium (in vivo). Additionally, in vitro experiments were designated as fol-
lows: control group—cardiomyocytes were incubated under normal conditions; DOX
group—cardiomyocytes were exposed to 1 µM DOX for 24 h; curcumin + DOX group:
cardiomyocytes were treated with curcumin (5, 10, 20, or 40 µM) for 22 h prior to DOX
exposure. SOD, GSH-Px and CAT activities along with MDA level, cell viability and
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the apoptosis rate were assessed to test ability of curcumin pretreatment to interact with
DOX-induced cardiotoxicity [92].
Curcumin pretreatment resulted in a significant suppression of oxidative stress, which
is one of the main components of toxicity provoked by DOX in rat cardiomyocytes.
2.7.4. Chalcones
Chalcones (trans-1,3-diphenyl-2-propen-1-ones), widely distributed in edible plants,
are precursors to all known flavonoids [93]. In in vitro studies, chalcones demonstrated an-
tioxidant and anti-inflammatory properties [94]. These compounds are believed to regulate
the activity of certain enzymes involved in DOX metabolism, e.g., aldo-keto reductases.
These reductases catalyze the formation of secondary alcohol metabolites, primarily dox-
orubicinol (DOXol) generated after the administration of DOX or daunorubicinol (DNRol)
arising after the administration of daunorubicin. Compounds such as DOXol and DNRol
are postulated to contribute to the development of cardiotoxicity [26].
The influence of the chemical structure of chalcones on the activity of cytoplasmic
reductases, which play an important role in the transformation of anthracyclines to car-
diotoxic derivatives such as DOXol and DNRol, was studied with the use of cytosolic
fraction from rabbit hearts and from human hearts. Twelve chalcones were examined, and
their activity was compared with the activity of quercetin and other flavonoids (Table 12).
The results provided evidence that chalcones, in particular 2’, 4’, and 2-trihydroxychalcone
(Table 2), affected the level of anthracycline metabolites (DOXol and DNRol) in the isolated
cytosols of rabbit and human hearts. Flavonoids, particularly quercetin, were demonstrated
to be effective inhibitors of DOXol and DNRol formation in the case of rabbit cytosol, and
DNRol inhibitors, but not DOXol inhibitors, in the case of human heart cytosol. In com-
parison, one of the most promising semi-synthetic flavonoids, monohydroxytlorutoside
(monoHER), had no effect on formation inhibition of the above-mentioned secondary
alcohol metabolites [95].
Table 12. Chalcone concentrations inhibiting by 50% (IC50) the formation of doxorubicinol (DOXol)
and daunorubicinol (DNRol) in hearts of DOX- or DNR-treated rabbits [26].
Compound IC50 [µM]
DOXol DNRol
2′,4′,2-trihydroxychalcone 21.2 ± 3.6 33.8 ± 4.4
2′,4′,3-trihydroxychalcone 30.9 ± 5.5 83.5 ± 6.9
2′,4′,2,3- tetrahydroxychalcone 25.3 ± 5.6 39.9 ± 4.5
2′,4′,2,4-tetrahydroxychalcone 32.8 ± 8.8 59.1 ± 9.1
quercetin 13.7 ± 2.8 8.0 ± 2.0
morin 49.3 ± 6.3 18.8 ± 4.1
These studies demonstrate the potential of chalcones as effective inhibitors of aldehyde
and carbonyl reductases in the heart. This is an important mechanism in protecting the
heart against the formation of secondary alcohol metabolites, and thus against DOX- or
DNR-induced cardiomyopathy [26].
2.7.5. Catechins
Catechins (Table 2) are flavonoids with a high degree of prevalence, with green tea
being a plant particularly rich in these compounds [96]. Catechins are known antioxidants,
free radical scavengers, and iron chelators. In vivo, these compounds exhibited beneficial
effects on the myocardium and prevented the development of atherosclerosis and car-
diac hypertrophy [97]. In addition, green tea extract helped to maintain the appropriate
cardiomyocytic architecture and their viability [98].
Given the above properties, the ability of catechin to prevent DOX-induced car-
diotoxicity in rats was tested [99]. The animals were administered i.v. DOX (at a dose of
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3 mg/kg/week), i.p. catechin (at a dose of 200 mg/kg/week), or catechin in combination
with DOX in different schemes:
• A scheme of 20 mg/kg catechin, followed 30 min by DOX;
• A scheme of 10 mg/kg catechin 30 min before and 1 h after DOX treatment;
• A scheme of 200 mg/kg catechin, followed 30 min by DOX;
• A scheme of 100 mg/kg catechin 30 min before and 1 h after administration of DOX;
• A scheme of 500 mg/kg catechin, followed 30 min by DOX.
The experiments were carried out for one month; their results are summarized in
Table 13.
Table 13. Effect of catechin on body weight, heart weight, atrial shrinkage, and Q-T interval in rats treated with DOX at a








CON 245.0 ± 9.5 47.7 ± 1.3 18.0 ± 2.3 26.0 ± 1.0
catechin (200 mg/kg) 224.7 ± 5.3 40.0 ± 2.1 12.1 ± 1.4 26.1 ± 3.4
DOX 204.3 ± 60.1 34.1 ± 1.2 9.3 ± 3.4 40.4 ± 1.3
catechin + DOX (20 mg/kg) 241.7 ± 10.9 44.7 ± 1.2 14.1 ± 2.3 32.2 ± 3.3
catechin (10 mg/kg) + DOX + catechin 240.0 ± 8.6 43.5 ± 2.6 13.7 ± 2.1 33.2 ± 3.1
catechin (200 mg/kg) + DOX 235.0 ± 6.6 38.8 ± 3.1 13.2 ± 3.4 33.5 ± 2.2
catechin (100 mg/kg) + DOX + catechin 237.1 ± 5.4 38.6 ± 2.1 13.1 ± 2.3 35.2 ± 1.1
catechin (500 mg/kg) + DOX 219.2 ± 5.3 37.8 ± 3.1 10.5 ± 3.0 35.7 ± 4.4
The greatest reduction in DOX toxicity was observed for rat hearts after the admin-
istration of catechin at a dose of 20 mg/kg. However, during the same experimental
cycle, an adverse effect of catechin on cardiac atrial contractility was demonstrated in rats
receiving this compound only (200 mg/kg) [99]. Another study found that catechin-rich
green tea could counteract the DOX-inducible modification of fatty acids in cardiomyocytes
in vitro [96]. Thus, the data from preclinical studies suggest that catechins may prevent
cardiotoxicity induced by DOX, yet further testing is necessary to determine whether they
can be an effective component of a chemotherapy-supporting diet in oncological patients.
2.7.6. Rutin
Rutin (rutinozide, Table 2) is a compound found in large quantities in buckwheat
(Fagopyrum esculentum Moench). Significant amounts of this phytochemical also occur,
among others, in elderberry, St. John’s wort, and sorrel. It has been suggested that rutin,
due to its antioxidant properties, could have a beneficial impact on human health. In the
context of chemotherapy with anthracyclines, the literature describes the effect of rutin
on the pharmacokinetics of idarubicin (IDA; an anthracycline antibiotic used clinically)
transformation into idarubicinol (IDol) in rat heart tissue. As with the anthracyclines
discussed earlier, the formation of secondary alcohol metabolites, such as IDol, is an
important factor responsible for IDA cardiotoxicity. During the performed tests, 0.5 mL of
IDA (1 mg/mL) was pumped through the heart of the animals for 1 min in the absence or in
the presence of rutin (10 µM). After completion of the experiments, IDA and IDol contents
were determined using HPLC. The results of the conducted research demonstrated that
in heart cells of animals exposed to IDA, rutin contributed to a significant reduction in
the amount of IDol produced (up to approx. 60%) [29]. This phytochemical, however,
did not affect the production of DOXol in the cytosol of human heart cells obtained
after autopsy [26]. The results of the above studies indicate that rutin could be an effective
cardioprotective factor during chemotherapy with the use of IDA. However, this compound
does not seem to ensure the protection of cardiac tissue cells against the side effects of DOX.
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2.7.7. Caffeic Acid Phenylethyl Ester
Caffeic acid phenylethyl ester (CAPE, Table 2) is a biologically active agent found
in propolis extract. This compound also occurs, among others, in pears, basil, thyme,
tarragon, turmeric, rosemary, hawthorn, and coffee. CAPE is a phenolic compound with
antioxidant properties [100]. Most likely owing to these properties, it was demonstrated
that i.p. administration of CAPE at a dose of 10 µmoles/kg/day resulted in a reduction
in cardiotoxicity in rats treated with a toxic dose of DOX (20 mg/kg). The animals were
administered DOX i.p., or DOX with CAPE (i.p., 2 days before and 10 days after DOX
treatment). The levels of relevant cardiotoxicity biomarkers were determined after 12 days
of treatment (Table 14).
Table 14. Effect of phenylethylene phenylethyl ester (CAPE) on the level of biomarkers of cardiotoxicity in the hearts of
DOX treated rats [100].











CON 100.0 ± 9.1 100.0 ± 10.2 100.0 ± 6.2 100.0 ± 10.1 100.0 ± 23.8 100.0 ± 27.3
DOX 168.8 ± 8.6 177.1 ± 12.1 116.4 ± 6.2 233.3 ± 13.8 238.0 ± 47.8 246.0 ± 37.4
CAPE + DOX + CAPE 207.0 ± 10.8 192.4 ± 12.1 166.7 ± 6.7 130.8± 8.7 131.2 ± 14.5 112.2 ± 33.8
a 100% CAT activity = 0.186 U/g protein; b 100% SOD activity = 0.157 U/mg protein; c 100% GSH-Px activity = 2.535 U/g
protein; d 100% MDA = 25.16 nmol/g tissue; e 100% myeloperoxidase activity = 1.207 mU/g protein; f 100% content of carbonyl
groups = 0.139 nmol/mg protein.
In the case of rats treated with CAPE + DOX, the activity of antioxidant enzymes was
significantly increased (nearly doubled), which probably contributed to the protection of
cardiac tissue against lipid peroxidation and protein oxidation (Table 14). In addition, the
structure of mitochondria in heart cells of rats treated with DOX + CAPE was similar to the
structure of mitochondria in control animal cells. The researchers concluded that CAPE
significantly affected the inhibition of DOX cardiotoxicity [101].
2.7.8. Oleuropein
Oleuropein is a polyphenolic compound that is present in high concentrations in
olive oil and leaves of the olive tree (Olea europaea L.). It has attracted attention in recent
years due to a variety of reported health benefits: cardioprotective, anti-inflammatory,
antioxidant, anti-cancer, anti-angiogenic and neuroprotective functions. Beyond these
actions, oleuropein has been reported to be capable of preventing DOX-induced cardiomy-
opathy [102]. Wistar rats with cardiotoxicity induced by DOX and treated with 1000 mg/kg
or 2000 mg/kg of oleuropein (i.p.) showed preserved heart left ventricle contractility,
attenuated inflammation and degenerative myocardial lesions, mitigated nitro-oxidative
stress and the decreased expression of pro-apoptotic mediators and the derangement of
myocardial metabolism.
2.7.9. Cannabinoids
Cannabinoids (the active constituents of Cannabis sativa L.) and their derivatives have
received considerable attention in recent years because of their extensive pharmacolog-
ical properties. Cannabinoids were first developed as successful agents for alleviating
chemotherapy-associated nausea and vomiting. Recent studies have revealed that cannabi-
noids have a wide range of therapeutic effects such as appetite stimulation, the inhibition of
nausea and emesis, the suppression of chemotherapy or radiotherapy-associated bone loss,
chemotherapy-induced nephrotoxicity and cardiotoxicity, pain relief, mood amelioration,
and relief from insomnia [103].
Among the phyto cannabinoids, cannabidiol (CBD) is a major nonpsychoactive con-
stituent of the plant C. sativa [104]. In a chronic model of DOX-induced cardiotoxicity in
rats, CBD was demonstrated to suppress myocardial toxicity via attenuating oxidative
stress, inflammation, and cell death pathways [105]. Recently, Hao et al. [106] demonstrated
that CBD attenuated DOX-induced cardiotoxicity via augmenting mitochondrial biogenesis
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and the blunting of oxidative and nitrative stress and apoptosis. It is noteworthy that CBD
also was shown to exert several cardioprotective actions against diabetic cardiovascular
complications [107] and has been approved in Canada and Europe for the management of
pain associated with multiple sclerosis. Cannabinoids’ function is mediated through CB1
and CB2 receptors and endogenous cannabinoid modulate their function. Interestingly, in
rat myocytes, both CB1 and CB2 receptors are expressed. Endogenous cannabinoids in the
ischemic condition exhibited a protective function via interacting with these receptors [108].
2.8. Other Cardioprotective Food Ingredients
2.8.1. Selenium and Vitamins A, C, E, D
Numerous studies have demonstrated that certain micronutrients, such as selenium,
vitamins A, C, and E administered orally, and vitamin D applied i.p., may also protect the
heart against cardiotoxicity induced by DOX [109–112]. The administration of vitamin A
prevented abnormalities in the hearts of rats exposed to DOX. It reduced the degree of lipid
and protein damage in the heart cells and inhibited lactate dehydrogenase and creatine
phosphokinase activity [110]. The administration of vitamin C to mice and guinea pigs
protected against DOX-induced lipid peroxidation and led to a reduction in the risk of acute
cardiotoxicity [113]. Vitamin E, administered to mice with DOX, decreased MDA levels
with the simultaneous increase in protein content and GSH and SOD activity [113]. The
systemic administration of vitamin D to rats, with DOX-induced cardiotomiopathy, caused
a significant decrease in the levels of Troponin T, blood urea nitrogen and CK enzyme. This
effect indicates that vitamin D can prevent damage to the rat myocardium and stabilize the
membrane [112].
The literature is inconclusive regarding the cardioprotective effects of vitamins during
chemotherapy in oncological patients, arousing controversy in the scientific community.
Results of preclinical studies involving mice and clinical trials in oncological patients
demonstrated that vitamin E protected the myocardium from the occurrence of acute
cardiotoxicity but did not prevent the development of chronic cardiac toxicity induced
by DOX [109]. Additionally, it was reported that vitamin E only slightly impacted heart
protection during cancer treatment [114,115]. The currently held belief is that there is insuf-
ficient evidence supporting the effectiveness of the antioxidant vitamins as cardioprotective
agents when administered together with anti-cancer drugs; thus, further studies are needed
to resolve this issue [116].
Selenium has also been tested for its ability to protect the myocardium against the
side effects of chemotherapy. Quiles [113] reported that the symptoms of DOX-induced
cardiomyopathy were suppressed in rats given selenium orally at a dose of 2.5 mg/kg for
8 weeks. This micronutrient also inhibited the development of cardiotoxicity in rabbits.
However, the protective effect of selenium in myocardia exposed to DOX has not been
confirmed in studies conducted with dogs [111] or mice [113].
2.8.2. Melatonin
Melatonin (5-methoxy-N-acetyltryptamine, Table 2), which is the regulator of the daily
human sleep and waking cycle, is a hormone produced by the pineal gland. It also occurs in
bacteria, protozoa, plants, fungi, invertebrates, and vertebrates [117]. In many edible plants
(e.g., mustard seeds, walnuts and groundnuts, asparagus, tomatoes, fresh mint leaves,
black tea), melatonin (MEL) occurs at even higher concentrations compared to the levels of
this hormone in human blood at night [118]. It is believed that it plays an important role as
an antioxidant, protecting biomolecules from damage caused by ROS [119–121].
Liu [31] tested MEL and its natural analogues, 6-hydroxymelatonin (6-OH MEL,
Table 2) and 8-methoxy-2-propionamidetetraline (8-M-PDOT) for their effects on DOX-
induced cardiotoxicity. Mice treated with DOX (25 mg/kg i.p.) and/or MEL, 6-OH-MEL,
8-M-PDOT were first used in the survival experiments. MEL and its analogues were ad-
ministered orally at doses 10 mg/L of water 24 h before the administration of a single, toxic
dose of DOX. Treatment with MEL and its analogues was continued for 5 days. After this
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time, the survival of the animals treated only with DOX and treated with DOX + 8-M-PDOT
was 50%. In the remaining groups, the protective effect of MEL and 6-OH MEL against
toxicity caused by DOX was observed [31]. To confirm the cardioprotective properties of
MEL and 6-OH MEL, measurements were made to assess cardiac function in vivo. Mice
were injected with a toxic dose of DOX (22.5 mg/kg i.p.) or saline (control group). MEL
(0.5 mg in 0.1 mL of 10% alcohol) or 6-OH MEL (0.5 mg in 0.1 mL of 10% DMSO) were
administered by a microosmotic pump (2.5 µg/h) 24 h before and for 5 days after treatment
with DOX. The following parameters of the heart function were determined:
• Left ventricular diastolic pressure (LVEDP);
• Left ventricular systolic pressure (LVESP);
• the first derivative of left-ventricular pressure after time (± dP/dt);
• Ejection volume (SV);
• Cardiac efficiency (CO).
Results are summarized in Table 15.












CON 4.8 ± 0.7 64.7 ± 3.8 2638 ± 127 2010 ± 248 9.7 ± 0.5 4.3 ± 0.5
DOX 10.7 ± 2.1 37.3 ± 5.5 904 ± 156 727 ± 153 4.1 ± 0.4 1.6 ± 0.3
MEL 3.0 ± 0.8 63.2 ± 3.2 2664 ± 120 1978 ± 163 9.2 ± 0.7 4.2 ± 0.6
MEL + DOX + MEL 4.3 ± 0.8 60.2 ± 1.2 1914 ± 95 1629 ± 143 7.4 ± 0.8 3.2 ± 0.4
6-OH MEL 4.5 ± 1.1 63.9 ± 4.4 2384 ± 334 1863 ± 299 9.5 ± 0.6 4.1 ± 0.5
6-OH MEL + DOX + 6-OH MEL 5.8 ± 0.5 57.0 ± 5.2 1774 ± 208 1586 ± 121 7.7 ± 0.6 3.0 ± 0.5
The results indicate that MEL and 6-OH MEL contributed to the improvement of
the contractile weakness caused by DOX [31]. There is substantial evidence that MEL
is an important antioxidant and that it contributes to the protection of the heart cell
membrane from lipid peroxidation, one of the factors responsible for the development
of DOX-stimulated cardiotoxicity [112,122–126]. The protective effect of MEL is also
explained by its contribution to increasing the level of GSH [123,126,127], the induction of
SOD activity [125], the stimulation of CAT activity [127], and the inhibition of zinc level
decline caused by DOX [122].
2.8.3. CoQ10 and L-Carnitine
Coenzyme Q (Q) is a key lipophilic compound for cell bioenergetics and membrane
antioxidant activities. It is an intracellular antioxidant that protects membrane phospho-
lipids, mitochondrial membrane protein, and LDL-cholesterol from free radical-induced
oxidative damage. It has been reported to be capable of recycling and regenerating other
antioxidants such as vitamin C and vitamin E [128]. As a cofactor, it plays a crucial role in
the mitochondria respiratory chain and ATP production [129].
L-carnitine is a non-protein amino acid (β-hydroxy-γ-trimethyl-amino-butyric acid)
that is synthesized from the essential amino acids, lysine and methionine. It is able to
scavenge free radicals, to protect antioxidant enzymes from oxidative damage, to maintain
the efficiency of the mitochondrial electron transport chain, and even to stimulate the
synthesis of antioxidant molecules, e.g., reduced GSH [130,131].
Considering above-mentioned facts, ameliorative potentials of CoQ10 or L-carnitine
on DOX-induced cardiotoxicity in rats were hypothesized [132]. The verifying study
was conducted on Wistar albino rats divided into six groups: control group; DOX group
(10 mg/kg); CoQ10 group (200 mg/kg); L-carnitine group (100 mg/kg); DOX + CoQ10
group; DOX + L-carnitine group. Oral treatment of CoQ10 and L-carnitine started 5 days
before a single dose of 10 mg/kg DOX that was injected intraperitoneally, then the treatment
was continued for 10 days. Cardioprotection was investigated by measuring oxidative
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stress, inflammatory and heart parameters and CoQ10 and L-carnitine effects are presented
in Table 16.
Table 16. Changes of oxidative stress parameters, inflammatory cytokine, and cardiac markers in
rats due to administration of CoQ10 or L-carnitine [132].
Group % MDA Level a % GSH Level b % TNF-α Level c % LDH Level d
CON 100.0 ± 24.5 100.0 ± 17.9 100.0 ± 11.1 100.0 ± 12.1
DOX 555.9 ± 80.2 77.3 ± 16.0 491.9 ± 30.9 400.2 ± 37.5
CoQ10 145.6 ± 14.1 118.9 ± 10.4 133.8 ± 56.6 95.4 ± 18.0
L-car 161.9 ± 19.0 123.6 ± 5.7 92.4 ± 9.8 104.2 ± 17.8
CoQ10 + DOX 345.5 ± 63.0 108.5 ± 9.4 179.5 ± 16.2 130.5 ± 18.2
L-car + DOX 347.7 ± 90.9 101.9 ± 7.5 282.3 ± 19.6 181.3 ± 15.4
a 100% MDA = 11.79 nM/g; b 100% GSH = 1.06 µM/g; c 100% TNF-α = 40.25 pg/mL; d 100% LDH = 100.80 U/mL.
The obtained results pointed out that both pretreatments by CoQ10 or L-carnitine
could restore measured parameters to control levels and suggested these compounds as
good candidates for protection of the myocardium integrity in DOX induced toxicity.
2.9. Semi-Synthetic Compounds with Cardioprotective Properties
2.9.1. MonoHER and Its Derivative Frederine
7-monohydroxyethylrutoside (monoHER) is a semi-synthetic flavonoid with antioxi-
dant properties. Systematic studies demonstrated that monoHER protected mice against
DOX-induced cardiotoxicity. The advantage of this compound was that it did not affect the
anti-tumor activity of DOX. However, to achieve full protection against the cardiotoxicity
of this anthracycline, it was necessary to use high doses of monoHER (500 mg/kg). Its
cardioprotective properties probably resulted from the ability to neutralize free radicals
and/or chelate iron ions implicated in ROS formation [133].
The results of early pre-clinical tests demonstrated DOX induced inflammation [134].
Therefore, monoHER was tested for anti-inflammatory properties in DOX-treated mice.
As an indicator of the inflammation of cardiac cells, N-(carboxymethyl)lysine (CML) was
used, an advanced glycation product formed in proteins by combined non-enzymatic
glycoxidation reactions. The anti-inflammatory properties of monoHER were tested by
determining the number of stained blood vessels containing CML and measuring the
intensity of this color. In these experiments, animals were treated with DOX (4 mg/kg
i.v.) or DOX in combination with monoHER (500 mg/kg i.v. 60 min before administration
of DOX). The monoHER significantly reduced the level of CML, which suggests that it
exhibits anti-inflammatory properties during DOX therapy [20].
A more recent study demonstrated that monoHER is a compound that is safe to
administer to healthy volunteers (at dose 1500 mg/kg), indicating its potential for reducing
the cardiac toxicity of DOX in treated cancer patients [135]. However, as noted, to achieve
complete protection against DOX-stimulated cardiotoxicity, it is necessary to use high
doses of monoHER. Taking monoHER as a lead structure, a series of new flavonoids
was synthesized, including a compound named Frederine, with the highest antioxidant
potential among the obtained derivatives [136]. It was then demonstrated that this semi-
synthetic flavonoid (at a dose of 68 mg/kg administered to mice i.p. for 6 weeks) exhibited
at least five times higher antioxidant activity than monoHER. Thus, in combination with
DOX, may be an even better cardioprotective factor [133].
2.9.2. Metformin
Metformin (MET) is a biguandine, synthesized in the 1920s from guanidine derived
from French lilac (Galega officinalis L.) and it is one of the most used oral antihypergly-
caemic drugs in the treatment of type 2 diabetes, taking its place in WHO’s Model Lists
of Essential Medicines [137,138]. Another interesting property of MET is its beneficial
impact to cardiovascular system, where MET-treated diabetes patients have less risk of
myocardial infarction [139]. This feature led to further investigations of MET’s potential
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use in circumstances where cardiotoxicity was observed as a side effect of initial treatment,
including radiotherapy or DOX chemotherapy [140,141].
Animal studies mostly used rats as a model and found cardioprotective properties of
MET in DOX-treated animals. Alhowail and Almogbel [129] observed the better overall
survival of DOX + MET-treated mice. Other studies found improvements in aortic flow
and cardiac output, myocytes thickness, degeneration, and other histopathological features
of heart tissue, interstitial inflammation, echocardiography parameters, and brain/heart
weight restoration when rats were MET + DOX-treated, compared to DOX-treated animals.
The results were accompanied with improvements in markers of membrane damage (LDH,
CK-MB, and Troponin T), as well as in autophagy proteins (LC3B-II) [142–146]. Regarding
the markers of oxidative stress, MET + DOX-treated rats showed a decrease in MDA (or
TBARS) concentration and restored GSH concentration and SOD activity compared to DOX-
treated animals, indicating that beneficial properties might be related to minimizing the
effects of oxidative stress [144–147] As a result of molecular changes in MET + DOX-treated
rats lower ratio of apoptosis and pro-apoptotic signaling (Caspase-3 activity, Bax/Bcl-2
ratio) contributing to the normal function of heart tissue [143].
Further mechanistic studies were carried out using rat and mouse cardiomyocytes
to investigate the role of certain signaling pathways and physiological changes in MET-
related cardioprotection from DOX treatment. Similarly, the studies found improvements
in cell viability, particularly in apoptosis decrease in MET + DOX-treated cells. This
effect was accompanied with the deregulation of pro-apoptotic signaling (Caspase-3, 8,
and 9, Bax/Bcl-2 ratio, and cytochrome c release) [143]. Again, studies showed that
MET + DOX-treated cardiomyocytes exhibited better oxidative status compared to DOX-
treated cells. The ROS and Ca2+ concentrations were lower and the activity of CAT, GPx,
and SOD activities improved in presence of MET [147]. DOX treatment of cardiomyocytes
induced changes to AMPK activity, ferritin heavy chain (FHC), adiponectin and its receptor
expression, mitochondrial activity, and NF-κB, ERK, and JNK signaling. However, DOX
treatment in conjunction with MET reversed these molecular changes and restored cell
phenotypes to exhibit properties more similar to unexposed controls [147]. Based on the
pre-clinical results, further in vivo studies are expected that might initiate clinical trials for
the prevention of DOX-induced cardiotoxicty by MET.
3. Strengths and Limitations
The current review represents a comprehensive database of natural compounds shar-
ing a particularly important common feature—the inhibition of cardiotoxic side effects
associated with the anthracycline treatment. Such a database represents a precious roadmap
for further clinical studies (Table 17). There are several limitations and potential knowledge
gaps present in this journey from bench to clinics.
The first is the extrapolation of data gained in pre-clinical in vitro and animal studies
to humans. Most of the results summarized in our review were gained in animal stud-
ies, but success in pre-clinical trials is usually not sustained during clinical trials, where
less than 10% of candidate drugs become approved [148,149]. Such disproportion could
be explained in differences in experimental design, inter-special differences, and dose
translation. Together with improvements in animal welfare, ethics in science, the 3Rs
principle, and the development of novel approaches in drug testing, we can expect the
number of animals used for pre-clinical studies to decline. However, animal research
remains essential in gaining information after all alternative in vitro and in silico methods
are drained [150–154]. It is therefore important to promote basic research using up-to-date
state-of-the art techniques and approaches to develop a candidate drug that will have
cardiopreventive properties without lowering the antitumor properties of the drug and the
efficacy of the therapy.
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Grapes ↓ ↓ ↑
Pomegranate ↓ ↓ ↑
Grapefruit ↓
Hawthorn ↓ ↓
Garlic ↓ ↓ ↓
Tomato ↓ ↓ ↑ ↓
Spinach ↓ ↓ ↓
Beetroot ↓ ↓
G. lucidum ↓ ↑ ↓ ↑
Wheat ↓ ↓ ↑
G. biloba ↓ ↓ ↑ ↓ ↑ ↓
Red sage ↓ ↓ ↓ ↑
Ginger ↓ ↓ ↑ ↑
Saffron ↓ ↓ ↑ ↑
P. urinaria ↓ ↑
Spirulina ↓ ↓ ↑ ↓ ↓
Seasamol ↓ ↓
Coumaric acid ↓ ↓
CAPE ↓ ↓ ↑ ↓ ↑
Oleuropein ↓ ↑ ↑ ↑ ↓
Cannabinoids ↓ ↑ ↑
Vitamin C ↓ ↓ ↑
Vitamin A ↓ ↓
Vitamin E ↓ ↓
Vitamin D ↓ ↓ ↑
Curcumin ↓ ↓ ↑ ↓ ↑ ↓
Catechins ↓ ↓ ↑ ↑ ↓
Melatonin ↓ ↓ ↑
CoQ10 ↓ ↑ ↑
L-carnitine ↓ ↑ ↑
Cardi-pro ↓ ↓ ↓ ↓
MonoHER ↓ ↑
Metformin ↓ ↓ ↑ ↑ ↓ ↑ ↓
Arrow downwards—decrease in the marker/property value; arrow upwards—increase in the marker/property
A second limitation of analyzing the comparative bioactivity of plant extracts is the
question of extract standardization, which is particularly important for herbal medicines
and is emphasized by regulatory bodies at the global level. For dietary supplements
and other less regulated health promotion products, this question is not so crucial. Stan-
dardization was defined by the American Herbal Product association: “Standardization
refers to the body of information and control necessary to product material of reasonable
consistency. This achieved through minimizing the inherent variation of natural product
composition through quality assurance practices applied to agricultural and manufac-
turing processes” [155]. If a principle active component is known, it is most logical to
measure and quantitate proposed compound. This approach has certain limitations, since
herbal extracts represent mixtures of many constituents that potentially all have different
bioactivities/different activity strengths. Additionally, herbal raw material is prone to a
lot of variation due to several factors, such as seasonal variation, ecotypic, genotypic and
chemotypic properties, and drying and storage conditions. Hence, the standardization of
plant extracts and potential herbal drugs is an overly complex issue that requires separate
investigation and was not a part of this review.
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4. Conclusions and Future Perspectives
Anthracycline antibiotics, including doxorubicin, are amazingly effective anticancer
drugs. However, their clinical use is limited by the dose-dependent development of car-
diotoxicity. The possibility of rational dietary intervention with phytochemicals and/or
supplementation with other natural ingredients to reduce cardiotoxicity is gaining in-
creased attention.
Nutritional interventions using plants with the appropriate composition of bioactive
compounds should be more thoroughly studied as a potentially safe and effective way
to prevent anthracycline-induced cardiotoxicity. The emphasis should also be focused to
cancer patients with previous or active heart disease that might be at greater risk for un-
wanted side effects. Childhood cancer survivors are also at increased risk of cardiovascular
complications in their adulthood [43]. A newly emerged challenge is the management
of COVID-19 in cancer patients receiving cardiotoxic antineoplastics in whom deterio-
rated lung function may be responsible for many additional cardiac events [156]. Thus,
prophylactic intervention is even more critical to prevent cardiotoxicity in this group.
However, it should be emphasized that very few studies have been conducted to date.
In addition, there is no data documenting the inhibition of the development of cardiotoxicity
(induced by anticancer drugs) by natural compounds in humans, and information available
in the literature can be the basis for drawing contradictory conclusions. Hence, both
pre-clinical and clinical trials in cancer patients are a major challenge in this area.
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